Trial NCT02462538

View at ClinicalTrials.gov 
Org. Study IDs: AGMT_ALCL1

Last trial update was posted on 2022-03-03

MeSH Interventions

Brentuximab Vedotin Imatinib Mesylate

MeSH Conditions

Lymphoma Lymphoma, Large-Cell, Anaplastic

Other Conditions

ALK+ Anaplastic Large Cell Lymphoma

Stopping Reasons

Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled patients

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID